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OBJECTIVES We sought to investigate whether activin A could be involved in the immunopathogenesis of
acute coronary syndromes.
BACKGROUND Inflammatory mechanisms seem to play a pathogenic role in atherosclerosis and acute
coronary syndromes, but the actual mediators have not been fully identified. Activin A, a
pleiotropic member of the transforming growth factor-beta cytokine family, has recently been
suggested to play a role in inflammation.
METHODS We examined the role of activin A and its endogenous inhibitor follistatin in patients with
stable (n  26) and unstable angina (n  20) and healthy control subjects (n  20) by
different experimental approaches.
RESULTS 1) Patients with stable angina had raised activin A concentrations, as assessed by protein levels
in serum and messenger ribonucleic acid levels in peripheral blood mononuclear cells
(PBMCs). 2) Although several activin A–related mediators were upregulated in PBMCs from
patients with stable angina compared with controls (i.e., activin A and Smad3), no changes
or even downregulation (i.e., Smad2) were seen in unstable disease. 3) The activin type II
receptors, representing the primary ligand-binding proteins, were downregulated in unstable
compared with stable angina. 4) Percutaneous coronary intervention induced a decrease in the
activin A/follistatin ratio, suggesting downregulatory effects on activin A activity. 5) Although
activin A dose-dependently suppressed the release of inflammatory cytokines from PBMCs
in angina patients, an opposite effect was found in healthy controls.
CONCLUSIONS Our findings suggest an anti-inflammatory potential of activin A in angina patients, and such
effects may be of particular relevance in unstable angina in which several of the activin
parameters were downregulated. (J Am Coll Cardiol 2004;44:369–75) © 2004 by the
American College of Cardiology Foundatione
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Pt is widely recognized that inflammatory mechanisms play
pathogenic role in coronary artery disease (CAD). In fact,
ecent research has suggested that inflammatory mediators
lay a causal role in several steps involved in the progression
f atherosclerosis from local inflammation through plaque
ormation and rupture (1–3). However, these inflammatory
ediators exert an array of biologic functions, and the
dentification and characterization of the different actors, as
ell as their relative importance, are not fulfilled.
Along with transforming growth factor (TGF)-beta and
one morphogenetic protein, activin A is a member of the
GF-beta superfamily (4). Although originally described as
n inducer of follicle-stimulating hormone release, activin A
as more recently been recognized as a multifunctional
ytokine expressed in a wide range of tissues and cells with
oles in regulation of wound repair, cell differentiation,
poptosis, and embryogenesis (4). Furthermore, growing
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Section of Endocrinology, §Section of Clinical Immunology and Infectious Dis-
ases, Rikshospitalet University Hospital, University of Oslo, Oslo; and Department
f Medicine, Bærum Hospital, Sandvika, Norway. This work was supported by the
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edinnova Foundation, Alf and Aagot Helgensen Legacy, Aktieselskapet Freia
hocoladefabriks Medical Foundation, and Blix Family Legacy.
Manuscript received December 16, 2003; revised manuscript received March 23,c004, accepted April 3, 2004.vidence implicates activin A in the pathogenesis of inflam-
atory disorders such as rheumatoid arthritis, sepsis, and
nflammatory bowel disease, possibly mediating anti-
nflammatory net effects (5–7). Recent studies suggest that
his cytokine could also be involved in atherogenesis by
nhibiting foam cell formation and inducing differentiation
f neointimal smooth muscle cells (8–10).
Based on its role in inflammation, in the present study,
e attempted to further clarify the potential role of activin
in atherogenesis and acute coronary syndromes by use of
everal experimental approaches. First, we examined protein
nd messenger ribonucleic acid (mRNA) levels of activin A
nd its natural inhibitor follistatin (4) in peripheral blood
rom patients with stable and unstable angina and healthy
ontrol subjects. Second, we investigated the expression of
he activin A signal transduction pathway involving the
eceptor-Smad system (4) in peripheral blood mononuclear
ells (PBMCs) from these individuals. Finally, we examined
he effect of activin A on the release of inflammatory
ytokines suggested to be involved in atherogenesis and
mmune-mediated plaque destabilization.
ETHODS
atients and controls. Angina patients undergoing clini-
ally indicated diagnostic coronary angiography in our
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Activin A in Acute Coronary Syndromes July 21, 2004:369–75oronary care unit were consecutively recruited into the
tudy (Table 1). All patients with unstable angina (n  20)
ad experienced ischemic chest pain at rest within the
receding 48 h (i.e., Braunwald class IIIB), but with no
vidence of myocardial necrosis by enzymatic criteria. Tran-
ient ST-T segment depression and/or T-wave inversion
ere present in all cases. All patients with stable angina
n  26) had stable effort angina lasting longer than six
onths and a positive exercise test. Exclusion criteria were
yocardial infarction or thrombolytic therapy in the previ-
us month, electrocardiographic abnormalities invalidating
T-segment analyses, concomitant inflammatory diseases
uch as infections and autoimmune disorders and liver or
idney disease. Coronary angiography was performed by
tandard techniques within one to two days after admission,
nd the diagnosis of CAD was confirmed by at least
ne-vessel disease, defined as 75% narrowing of the
uminal diameter, in all patients. Control subjects in the
tudy were 20 gender- and age-matched healthy blood
onors. Informed consent for participation in the study was
btained from all individuals.
lood sampling protocol. Peripheral venous blood was
rawn into pyrogen-free tubes without additives (serum) or
ith ethylenediamide tetra-acetic acid as an anticoagulant
plasma). The tubes were immediately immersed in melting
ce and centrifuged at 1,500 g for 10 min within 20 min
plasma) or allowed to clot before centrifugation (serum).
ll samples were stored at 80°C and thawed less than
hree times.
ell culture experiments. The PBMCs (2 106 cells/ml),
btained from heparinized blood by Isopaque-Ficoll gradi-
nt centrifugation (Lymphoprep; Nycomed, Oslo, Norway),
ere incubated in 96-well trays (Costar, Cambridge, Mas-
achusetts) in medium alone (RPMI 1640 with 2 mmol/l
-glutamine [Gibco, Paisley, United Kingdom] supple-
ented with 10% fetal calf serum) or stimulated with
ifferent concentrations of activin A (R&D Systems, Min-
eapolis, Minnesota). Cell-free supernatants were harvested
fter 18 h and stored at 80°C. Activin A levels were also
xamined in platelet-rich plasma activated by the throm-
in receptor agonist SFLLRN (11). Endotoxin levels in
ll media, buffers, and stimulants were 10 pg/ml
limulus amoebocyte lysate test; BioWhittaker, Walkers-
Abbreviations and Acronyms
CAD  coronary artery disease
EIA  enzyme immunoassay
IL  interleukin
MIP  macrophage inflammatory protein
mRNA  messenger ribonucleic acid
PBMC  peripheral blood mononuclear cell
PCI  percutaneous coronary intervention
TGF  transforming growth factor
TNF  tumor necrosis factorille, Maryland). ceal-time quantitative reverse transcription polymerase
hain reaction. Total RNA was extracted from PBMCs
sing RNeasy columns (Qiagen, Hilden, Germany), sub-
ected to DNase I treatment (RQI DNase; Promega,
adison, Wisconsin) and stored at 80°C. Primers were
esigned using the Primer Express software version 1.5
Applied Biosystems, Foster City, California) (Table 2).
uantification of mRNA was performed using the ABI
rism 7000 (Applied Biosystems) (12). SyBr green assays
Table 2) were performed using 300 nmol/l sense and
nti-sense primers (12). Gene expression of the housekeep-
ng gene beta-actin (Applied Biosystems) was used for
ormalization.
nzyme immunoassay (EIA). Interleukin (IL)-6, IL-8,
L-10, macrophage inflammatory protein (MIP)-1-alpha,
onocyte chemoattractant protein-1, TGF-beta, and tumor
ecrosis factor (TNF)-alpha were measured by EIA (R&D
ystems). Activin A was analyzed by EIA from Serotec
Oxford, United Kingdom; serum with pretreatment of
amples according to the manufacturer’s description) and
&D Systems (plasma). Follistatin levels were measured by
IAs provided by R&D Systems.
tatistical analysis. When comparing three groups of in-
ividuals, one-way analysis of variance was followed by the
cheffe´ post hoc test for statistical significance. For com-
arisons within the same individuals, the Wilcoxon signed-
ank test was used. Probability values (two-sided) were
onsidered significant at value of 0.05.
ESULTS
irculating levels of activin A and follistatin. As shown
n Figure 1A, both patients with stable (n  26) or unstable
ngina (n  20) had significantly increased serum levels of
ctivin A, compared with healthy controls (n 20), with no
ignificant differences between the two groups of CAD
atients. In contrast, we found no differences in plasma
evels of follistatin between these three groups of individuals
Fig. 1B). Notably, although activin A levels in the patient
roup as a whole were significantly correlated with serum
evels of C-reactive protein (r  0.32, p  0.05), no such
able 1. Characteristics of the Study Group
Unstable
Angina
(n  20)
Stable
Angina
(n  30)
ge (yrs) 58  13 58  9
ender (females/males) 2/18 5/26
mokers (%) 31 32
edication (%)
Beta-blockers 94 91
Aspirin 94 91
Statins* 65 71
Calcium antagonists 24 11
Warfarin 12 14
Hydroxymethylglutaryl coenzyme A reductase inhibitors. Data are presented as the
ean value  SD or percentage.orrelation was found for follistatin (r  0.14, p  0.49).
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July 21, 2004:369–75 Activin A in Acute Coronary SyndromesMeasurement in serum samples could potentially be
nfluenced by release from platelets during ex vivo coagula-
ion. However, we found no release of activin A or follistatin
rom SFLLRN-stimulated platelets in either patients or
ontrols. It has previously been reported that heparin
nduces a rapid increase in serum levels of activin A and
ollistatin (13), but importantly, all blood samples were
ollected before heparin administration.
ene expression of activin betaA and follistatin in PBMCs.
ctivin A is a homodimer of two activin betaA subunits (4),
nd we next examined the gene expression of activin betaA
nd follistatin in PBMCs from 15 patients with stable
ngina, 15 patients with unstable angina, and 10 healthy
ontrols. Although activin betaA gene expression was sig-
ificantly upregulated in PBMCs from patients with stable
ngina, no such increase was found in those with unstable
isease (Fig. 2A). Thus, while serum activin A levels were
aised in both stable and unstable angina patients, only
hose with stable disease had increased expression of this
ytokine in PBMCs. This apparent discrepancy most prob-
bly reflects that cells other than PBMCs, such as macro-
hages, endothelial cells, mast cells, fibroblasts, and vascular
mooth muscle cells, are major contributors to serum levels
f activin A (4,6). As for follistatin expression, no differ-
nces were found between patients and controls or between
he two patient groups (data not shown).
xpression of activin A receptors and Smads in PBMCs.
e next examined the gene expression of activin A recep-
ors (type I and II; Table 2) and Smads in PBMCs from
hese 15 patients with unstable angina, 15 patients with
table angina, and 10 healthy controls. The signal transduc-
ion pathway involving the receptor-Smad system is highly
imilar for the TGF-beta family members, including activin
(4,14), and notably, unstable angina patients had de-
reased gene expression of the activin type II, IIA, and IIB
eceptors, representing the primary ligand-binding proteins
Table 2. Characteristics of the Real-Time Poly
Target Sequen
Activin betaA ()-GCAGAAATGAA
()-GTCTTCCTGGC
ActRIA ()-CGAGACGTGGA
()-CGAATGATCCA
ActRIB ()-GTGGGCACCCA
()-GCTATGGCACA
ActRIIA ()-TTGGCAGAAAC
()-ATCTGGGTAAT
ActRIIB ()-GCACCATCGAG
()-CCACACACTCC
Smad2 ()-CCTCTGGATGA
()-GGAGGTGGCGT
Smad3 ()-TCCCACCAGGA
()-GCACATTCGGG
Smad7 ()-AGCCGACTCTG
()-GACAGTCTGCA
This table shows the sequence of primers used in the real-ti
()  forward primers; ()  reverse primers; Acc. Nr.4,14), compared with those with stable disease (Figs. 2B *nd 2C). Moreover, as shown in Figure 3, a similar pattern
ith decreased levels in unstable compared with stable
ngina was also seen for the gene expression of the intra-
ellular proteins Smad2 and Smad3, which bind to the
ctivin A heterocomplex upon ligand binding, representing
he principal transducer of signals from the receptors (14).
n fact, although Smad2 expression was significantly de-
reased in unstable angina patients compared with healthy
ontrols, Smad3 expression was increased in stable angina
atients compared with healthy individuals (Fig. 3), sug-
igure 1. (A) Serum levels of activin A and (B) plasma levels of follistatin
n 20 patients with unstable angina pectoris (AP), 26 patients with stable
P, and 20 healthy controls. Data are presented as the mean value SEM.
se Chain Reaction Assays Used in the Study
33) Acc. Nr.
ACTTATGGA M13436
TCCTGACT
TGGCACTA Z22534
AATCTGCTAAAGT
GAA NM_004302
GCCATT
CTGGAA M93415
TTCACCTACACA
GTGAA X77533
CTATCGT
TACTCACTCCATT NM_005901
TGGAA
AACCT NM_005902
ACTGGTA
ACTAGAGT NM_005904
GGTTTGAGA
lymerase chain reaction assays.
nBank accession number; Act  activin; R  receptor.mera
ce (5
TGA
TGT
GTA
ATA
AGG
CAT
ATG
TCT
CTC
TGC
CTA
TTC
TGC
TCA
CGA
GTT
me pop  0.05 and **p  0.01 versus healthy controls.
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Activin A in Acute Coronary Syndromes July 21, 2004:369–75esting that the Smad system may be differently or even
ppositely regulated in stable and unstable disease. In
ontrast, no differences were found in mRNA levels of the
nhibitory Smad7 (Fig. 3C) or the activin type I receptors
data not shown) between either unstable and stable angina
atients or between patients and controls.
ffect of percutaneous coronary intervention (PCI) on
ctivin A and follistatin levels. To examine the expression
attern of activin A and follistatin upon inflammatory
timulation in vivo, we next examined plasma levels of
ctivin A and follistatin in 14 patients with stable angina
nd 13 patients with unstable angina before and 48 h after
CI. Heparin has been shown to induce a rapid increase in
oth activin A and follistatin levels (13), and indeed,
mmediately after PCI there was an early (i.e., within 1 h)
igure 2. Gene expression of the activin A subunit activin betaA (A) and
he activin A receptor II type A (ARIIA) (B) and type B (ARIIB) (C) in
eripheral blood mononuclear cells from 15 patients with unstable angina
ectoris (AP), 15 patients with stable AP, and 10 healthy controls. The
essenger ribonucleic acid (mRNA) levels were quantified using real-time
everse transcription polymerase chain reaction, and data are presented
elative to the gene expression of beta-actin (mean  SEM). *p  0.05
ersus healthy controls. †p  0.05 versus stable AP.ise in these cytokines, returning to baseline levels within eh; as for activin A, there was a subsequent late decrease in
he concentration, reaching significantly lower levels than
aseline after 48 h (Fig. 4). In contrast, after returning to
aseline levels within 4 h, follistatin increased, reaching
ignificantly higher levels than baseline at 48 h after PCI
Fig. 4). We found a similar pattern in both stable and
nstable angina patients, although the decrease in activin A
id not reach statistical significance in those with unstable
isease (Fig. 4).
ffects of activin A on cytokine levels in PBMCs. In
ontrast to several reports on inflammatory cytokines, ac-
ivin A levels seem to be equal (serum) or even lower
PBMCs) in unstable compared stable angina patients. To
ap any possible pathogenic consequences of decreased
ctivin A activity with respect to plaque rupture, we next
igure 3. Gene expression of Smad2 (A), Smad3 (B), and Smad7 (C) in
eripheral blood mononuclear cells from 15 patients with unstable angina
ectoris (AP), 15 patients with stable AP, and 10 healthy controls. The
essenger ribonucleic acid (mRNA) levels were quantified using real-time
uantitative reverse transcription polymerase chain reaction, and data are
resented relative to the gene expression of beta-actin (mean  SEM). *p 
.05 versus healthy controls. †p  0.05 versus stable AP.xamined the effect of activin A on the release of inflam-
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July 21, 2004:369–75 Activin A in Acute Coronary Syndromesatory cytokines, suggested to be involved in plaque desta-
ilization (3), in PBMCs from seven patients with stable
ngina, six patients with unstable angina, and six healthy
ontrols. Several significant findings were revealed (Fig. 5).
irst, activin A induced a significant and dose-dependent
ecrease in the release of the inflammatory cytokines IL-6,
L-8, and MIP-1-alpha, but not TNF-alpha, in both stable
nd unstable angina patients. In contrast to this suppressive
ffect, activin A dose-dependently increased the release of
L-6, TNF-alpha, and MIP-1-alpha from PBMCs in
ealthy controls, with a particularly enhancing effect on
IP-1-alpha (10-fold increase). Finally, in contrast to
he effects on inflammatory cytokines, activin A had no
ffect on TGF-beta or IL-10 in either patients or controls
data not shown), indicating that the suppressive effects of
ctivin A on inflammatory cytokines in unstable angina
atients do not involve regulation of these typically anti-
nflammatory cytokines.
ISCUSSION
ctivin A and follistatin have previously been reported to be
xpressed in human vascular tissue at different stages of
therosclerosis (9). In the present study, we extend these
ndings by showing raised activin A concentrations as
ssessed by protein levels in serum and mRNA levels in
BMCs in patients with stable angina. However, whereas
umerous reports on inflammatory cytokines have demon-
trated the highest levels in those with unstable disease
11,15–18), this was not seen for activin A and related
arameters. In fact, although several of these parameters
igure 4. Plasma levels of activin A and follistatin in 14 patients with stable
ngina pectoris (AP) (A and C) and 13 patients with unstable AP (B and D)
efore (Pre) and 48 h after (Post) percutaneous coronary intervention (PCI).
ctivin A levels were only measured in 11 of the patients with unstable AP.ere upregulated in stable angina patients compared with kealthy controls (i.e., activin betaA and Smad3), no changes
r even downregulation (i.e., Smad2) were seen in unstable
isease. Moreover, the activin type II receptors, representing
he primary ligand-binding proteins, were downregulated in
nstable compared with stable angina. Although we found a
imilar pattern of responses to activin A in PBMCs from
oth stable and unstable angina patients, the different and
ven opposite regulation of several activin-related parame-
ers in these two groups of angina patients suggest that this
ystem may be of importance in the progression from stable
o unstable disease. Interestingly, the TGF-beta type II
eceptor has been reported to be profoundly decreased in
dvanced atherosclerotic lesions (19), and it is tempting to
ypothesize that also dysregulated expression of activin A
nd its receptors, being a related member of the TGF-beta
uperfamily, could contribute to atherogenesis and plaque
estabilization.
Activin A has been suggested to promote plaque stabili-
ation by inhibiting foam cell formation through regulating
cavenger receptor mRNA expression and by inducing a
ontractile, nonproliferative phenotype in cultured smooth
uscle cells (8,9). Herein we show that activin A dose-
ependently attenuated the release of IL-6, IL-8, and
IP-1-alpha in PBMCs from CAD patients, suggesting
hat an “inadequate rise” in activin A could contribute to an
nappropriate inflammatory response in these patients.
oreover, all these cytokines are expressed within athero-
clerotic plaques, with particularly high levels in advanced
esions (2,3,20,21), and may enhance plaque rupture
hrough various mechanisms such as promotion of matrix
egradation and apoptosis (3,13,21). Interestingly, TGF-
eta has recently been shown to inhibit chemokine expres-
ion through Smad-related pathways (22), and similar
echanisms could also be operating in the activin A–
ediated inhibition of inflammatory cytokines. Whatever
he mechanisms, our findings with markedly suppressive
ffects of activin A on inflammatory cytokines in CAD
atients, along with decreased or inadequately raised levels
f several activin A–related mediators in unstable angina,
urther support a potential role for activin A in the patho-
enesis of plaque destabilization.
A major finding of the present study was that in contrast
o the anti-inflammatory effects of activin A in PBMCs
rom CAD patients, this cytokine markedly enhanced the
elease of inflammatory cytokines in PBMCs from healthy
ontrols. There is a growing appreciation of the importance
f activin A as a modulator of immune function, showing
oth inflammatory and anti-inflammatory effects (6,23).
hus, activin A has been reported to inhibit IL-1 and IL-6
ctivity by both inhibiting their production and antagoniz-
ng their action (23,24). On the other hand, activin A has
een found to enhance IL-6 and IL-8 expression during
regnancy (25) and to increase IL-6 levels in monocytes
26), and our findings further underscore the dichotomy
etween pro- and anti-inflammatory actions of this cyto-
ine. Similar pleiotropic effects have also been reported for
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Activin A in Acute Coronary Syndromes July 21, 2004:369–75GF-beta, the prototypical cytokine in the TGF-beta
uperfamily (27). The reason for these different responses in
BMCs from angina patients and healthy controls is un-
lear at present, but may involve several factors such as a
ifferent degree of pre-activation, different expression pat-
ern of the activin A receptors and Smads, and changes in
evels of co-activators and co-repressors, as well as other
ranscriptional factors (14). Nevertheless, these findings
nderscore that caution is needed when interpreting the
elevance of studies in healthy individuals with respect to
AD and similar disorders.
Several observations have linked the activin A/follistatin
ystem to the acute-phase response during inflammation
6,23). The rapid rise of activin A during such responses has
een suggested to induce anti-inflammatory effects both
ocally at the site of the injury or infection and at peripheral
ites such as the liver, attempting to prevent an inappropri-
te inflammatory response (23). The findings of the present
tudy may suggest an anti-inflammatory potential of this
ytokine also in CAD patients with marked downregulatory
ffects on several inflammatory cytokines in mononuclear
ells from these patients. Such effects may be of particular
elevance in unstable angina patients in whom several of the
ctivin parameters were downregulated. In addition to its
reviously demonstrated role in foam cell inhibition and
igure 5. The effect of activin A (10 and 100 ng/ml) on the protein levels of
C), and tumor necrosis alpha (TNF)-alpha (D) in peripheral blood mononu
ars), seven patients with stable AP (striped bars), and six healthy controls (o
.05 versus unstimulated cells.mooth muscle cell stabilization, our findings suggest thatctivin A could represent a new therapeutic target in CAD
nd acute coronary syndromes.
eprint requests and correspondence: Dr. Pål Aukrust, Section
f Clinical Immunology and Infectious Diseases, Medical Depart-
ent, Rikshopitalet, Sognsvannsveien 20, 0027 Oslo, Norway.
-mail: pal.aukrust@rikshospitalet.no.
EFERENCES
1. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med
1999;340:115–26.
2. Hansson GK, Libby P, Scho¨nbeck U, Yan ZO. Innate and adaptive
immunity in the pathogenesis of atherosclerosis. Circ Res 2002;91:
281–91.
3. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new
mechanisms and clinical targets. Nat Med 2002;8:1257–62.
4. Chen YG, Lui HM, Lin SL, Lee JM, Ying SY. Regulation of cell
proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med
2002;227:75–87.
5. Gribi R, Tanaka T, Harper-Summers R, Yu J. Expression of activin A
in inflammatory arthropathies. Mol Cell Endocrinol 2001;180:163–7.
6. Phillips DJ, Jones KL, Scheerlinck JY, Hedger MP, de Kretser DM.
Evidence for activin A and follistatin involvement in the systemic
inflammatory responses. Mol Cell Endocrinol 2001;180:155–62.
7. Hubner G, Brauchle M, Gregor M, Werner S. Activin A: a novel
player and inflammatory marker in inflammatory bowel disease? Lab
Invest 1997;77:311–8.
8. Kozaki K, Akishita M, Eto M, et al. Role of activin-A and follistatin
in foam cell formation of THP-1 macrophages. Arterioscler Thromb
ukin (IL)-6 (A), IL-8 (B), macrophage inflammatory protein (MIP)-1-alpha
ells supernatants from six patients with unstable angina pectoris (AP) (solid
ars) after culturing for 18 h. Data are given as the mean value  SEM. *p interle
clear c
pen bVasc Biol 1997;17:2389–94.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
375JACC Vol. 44, No. 2, 2004 Smith et al.
July 21, 2004:369–75 Activin A in Acute Coronary Syndromes9. Engelse MA, Neele JM, van Achterberg TA, et al. Human activin-A
is expressed in the atherosclerotic lesion and promotes the contractile
phenotype of smooth muscle cells. Circ Res 1999;85:931–9.
0. Engelse MA, Lardenoye JH, Neele JM, et al. Adenoviral activin A
expression prevents intimal hyperplasia in human and murine blood
vessels by maintaining the contractile smooth muscle cell phenotype.
Circ Res 2002;90:1128–34.
1. Aukrust P, Mu¨ler F, Ueland T, et al. Enhanced levels of soluble and
membrane-bound CD40 ligand in patients with unstable angina—
possible reflection of T lymphocyte and platelet involvement in the
pathogenesis of acute coronary syndromes. Circulation 1999;100:
614–20.
2. Yndestad A, Holm AM, Mu¨ller F, et al. Enhanced expression of
inflammatory cytokines and activation markers in T-cells from patients
with chronic heart failure. Cardiovasc Res 2003;60:141–6.
3. Phillips DJ, Jones KL, McGaw DJ, et al. Release of activin and
follistatin during cardiovascular procedures is largely due to heparin
administration. J Clin Endocrinol Metab 2000;85:2411–5.
4. Itoh S, Itoh F, Goumans MJ, Ten Dijke P. Signaling of transforming
growth factor-beta family members through Smad proteins. Eur
J Biochem 2000;267:6954–67.
5. Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of
interleukin-6 in unstable angina. Circulation 1996;94:874–7.
6. Aukrust P, Berge RK, Ueland T, et al. Interaction between chemo-
kines and oxidative tress: possible pathogenic role in acute coronary
syndromes. J Am Coll Cardiol 2001;37:485–91.
7. Yamashita H, Shimada K, Seki E, Mokuno H, Daida H. Concentra-
tions of interleukins, interferon, and C-reactive protein in stable and
unstable angina pectoris. Am J Cardiol 2003;91:133–6.8. Wæhre T, Halvorsen B, Damås JK, et al. Inflammatory imbalancebetween IL-10 and TNF in unstable angina—potential plaque
stabilizing effects of IL-10. Eur J Clin Invest 2002;32:803–10.
9. McCaffrey TA. TGF- and TGF- receptors in atherosclerosis.
Cytokine Growth Factor Rev 2000;11:103–14.
0. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of
angiotensin II and interleukin 6 in human coronary atherosclerotic
plaques: potential implications for inflammation and plaque instability.
Circulation 2000;101:1372–8.
1. Boisvert WA, Curtiss LK, Terkeltaub RA. Interleukin-8 and its
receptor CXCR2 in atherosclerosis. Immunol Res 2000;21:129–37.
2. Feinberg MW, Shimizu K, Lebedeva M, et al. Essential role for
Smad3 in regulating MCP-1 expression and vascular inflammation.
Circ Res 2004;94:601–8.
3. de Kretser DM, Hedger MP, Phillips DJ. Activin A and follistatin:
their role in the acute phase reaction and inflammation. J Endocrinol
1999;161:195–8.
4. Ohguchi M, Yamato K, Ishihara Y, et al. Activin A regulates the
production of mature interleukin-1 and interleukin-1 receptor an-
tagonist in human monocytic cells. J Interferon Cytokine Res 1998;
18:491–8.
5. Keelan JA, Zhou RL, Mitchell MD. Activin A exerts both pro- and
anti-inflammatory effects on human term gestational tissues. Placenta
2000;21:38–43.
6. Yamashita N, Nakajima T, Takahashi H, Kaneoka H, Mizushima Y,
Sakane T. Effects of activin A on IgE synthesis and cytokine
production by human peripheral mononuclear cells. Clin Exp Immu-
nol 1993;94:214–9.
7. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-
beta: pleiotropic role in the regulation of hematopoiesis. Blood
2000;96:2022–36.
